semaglutide and bariatric surgery The Potential of Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Surgery—a Retrospective Analysis | Obesity GLP-1 After Bariatric Surgery: Safety

Realistic Expectations: 3 to 6 Months of Treatment After 12 weeks of GLP-1 therapy, most patients have lost 10 to 25 pounds and are experiencing stable appetite control, reduced food preoccupation, and improved relationship with portion sizes

Orforglipron, made by the same company that produces the GLP-1 medications Zepbound and Mounjaro (tirzepatide), is an oral medication undergoing FDA clinical tests for use in weight loss

Lab monitoring is mainly pathway-based because routine clinical monitoring standards are not established for this peptide

What the evidence shows Where the real trial data sits, why the strongest human evidence is for semaglutide rather than retatrutide, and how to hold both without overstating either

Nature 527(7577):186191

It is also important to look at the probability of losing weight